Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The surge in international companies wanting to partner in Korea reflects a flourishing South Korean pharma economy, which, in recent years, has become the third largest pharma region in Asia. 19 July 2017
UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) today published its updated clinical guideline on Parkinson's disease. 19 July 2017
A white paper with input from a host of experts from big pharma has looked into the extent to which the US market is moving towards value-based contracts that reward manufacturers on outcomes rather than volume. 19 July 2017
Gedeon Richter has been granted marketing authorization from the European Commission for Reagila (cariprazine), a novel antipsychotic for the treatment of schizophrenia in adult patients. 19 July 2017
Japanese drugmakers JCR Pharmaceuticals and Teijin today announced that they have entered into a co-development and license agreement regarding JTR-161. 19 July 2017
The launch of a new Russian-Nicaraguan vaccine production, which was recently established in the city of Managua with the aim of becoming one of the largest in Central and Latin America, will be postponed for the end of the current year, according to press-service of the Russian Ministry of Health. 19 July 2017
Swiss pharma giant Novartis is considering accelerating expansion in the Russian market of anti-cancer drugs in the coming years, according to the company. 19 July 2017
The Canadian pharmaceutical market is set to grow from $22.6 billion in 2016 to around $25 billion by 2021, representing a compound annual growth rate of 2%. 19 July 2017
US health care giant Johnson & Johnson was 1.3% up at $133.91 on Tuesday lunchtime after investors reacted positively to the presentation of its 2nd-qtr results, although sales in its pharma segment were in fact down on a year ago. 18 July 2017
Novartis’ shares were up 2.25% at 81.95 Swiss francs in morning trading, after the company posted second-quarter 2017 financial results that beat expectations, and reiterated its forecast that sales would start growing again in 2018. 18 July 2017
The Association of the Russian Pharmaceutical Manufacturers (ARPM) has reported on a meeting of the Russian Chamber of Commerce and Industry Committee. 18 July 2017
Beleaguered Canadian firm Valeant Pharmaceuticals International (TSX: VRX) has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I. 18 July 2017
Spain's leading drugmaker Almirall has launched a new research project, dubbed Nano4Derm, to investigate ways that nanomedicine can be used to treat dermatological diseases. 18 July 2017
The pharmaceutical industry is a prime target for hackers. In 2015, a survey by Crown Records Management revealed that nearly two thirds of pharma firms had experienced breaches in data, and that one fourth of these same companies had been victims of hacking. 18 July 2017
As a lifelong follower of the so-called ‘tau hypothesis’, TauRx Therapeutics chief executive Claude Wischik ploughed a lonely furrow for many years. 18 July 2017
The American biotech firm Alzheon has unveiled data being presented at the Alzheimer’s Association International Conference (AAIC), in London. 17 July 2017
A study conducted at New York University has shown that combining memantine hydrochloride with a care management program can multiply the improvement in daily function in Alzheimer’s patients by up to 750%. 17 July 2017
The USA’s Federal Trade Commission has approved a sub-license submitted by UK-incorporated Mallinckrodt, granting West Therapeutic Development certain rights to develop and market the specialty drug Synacthen Depot (tetracosactide) in the USA. 17 July 2017
Spain-based Noventure and the Italian subsidiary of France’s Pierre Fabre have entered into an agreement in which Pierre Fabre will distribute Noventure’s Aprotecol in Italy. 17 July 2017